STOCK TITAN

Summit Therapeutics (SMMT) Stock News

SMMT NASDAQ

Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.

Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.

Rhea-AI Summary

Summit Therapeutics (SMMT) received an FDA Complete Response Letter rejecting its ivonescimab application in its present form for previously treated lung cancer. The application covers ivonescimab plus platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer after EGFR-targeted therapy. The FDA found effectiveness unestablished without a statistically significant overall survival improvement and said the progression-free survival benefit did not support a positive benefit-risk profile without that survival result.

The Phase III HARMONi trial met its progression-free survival endpoint, measuring time without cancer worsening, but not its overall survival endpoint. A post-hoc follow-up analysis reported an overall survival hazard ratio of 0.76 in the full, Asian and western populations. Summit continues Phase II and III development across lung, colorectal, urothelial and kidney cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Summit Therapeutics (NASDAQ: SMMT) reported clinical progress and quarterly financial highlights, including a $2 billion equity investment from AstraZeneca received after quarter-end. Cash and investments totaled $629.8 million at September 30, 2026.

The FDA's target action date for ivonescimab plus chemotherapy in previously treated EGFR-mutated advanced lung cancer is November 14, 2026. HARMONi met its primary progression-free survival endpoint, but its primary overall survival analysis was not statistically significant; the FDA said a significant survival benefit is necessary for authorization in this setting. Enrollment in both HARMONi-3 cohorts is complete, with the squamous cohort's progression-free survival event threshold expected in Q4 2026. Summit also expanded bladder and kidney cancer studies and clinical collaborations. Akeso's China trials reported significant overall survival benefits in lung and biliary tract cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.24%
Tags
-
Rhea-AI Summary

Summit Therapeutics (SMMT) reported that ivonescimab plus chemotherapy improved overall survival versus durvalumab plus chemotherapy in advanced biliary tract cancer.

Partner Akeso’s China-only Phase III HARMONi-GI1 trial enrolled 682 patients. At an interim analysis with 14.3 months’ median follow-up, median overall survival was 14.9 versus 12.1 months. The hazard ratio was 0.75, representing a 25% reduction in death risk, with statistical significance. Median progression-free survival—time without cancer worsening—was 8.4 versus 5.8 months. Response rates were 53.8% versus 32.5%. Serious treatment-emergent adverse events occurred in 43.4% versus 43.7%.

Summit expects U.S. site activation for its ECOG-ACRIN Phase II/III BTC study to begin in Q4 2026. It will compare ivonescimab plus chemotherapy with pembrolizumab or durvalumab plus chemotherapy, with overall survival as the primary endpoint.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
none
Rhea-AI Summary

Summit Therapeutics (SMMT) entered a research agreement with Lunit to evaluate AI-powered pathology analysis for its ivonescimab development programs.

The research will apply Lunit SCOPE IO to whole-slide tissue images stained with hematoxylin and eosin, a routine tissue stain. It will characterize the tumor microenvironment—the cells and structures surrounding a tumor. The companies aim to explore how this analysis could support biomarker discovery, patient grouping or selection, and understanding of responses to ivonescimab, an investigational antibody targeting PD-1 and VEGF.

The companies expect insights that may inform future research and clinical development planning. No clinical outcome data accompany the agreement. Lunit SCOPE products are for research use only, not diagnostic procedures or decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
AI
-
Rhea-AI Summary

Summit Therapeutics (NASDAQ: SMMT) announced ivonescimab findings across multiple tumor types, including clinical results supporting expansion of its endometrial cancer study. Ten presentations are scheduled at ESMO 2026 in Madrid, October 23–27. They include positive overall survival findings from Akeso’s China-based Phase III HARMONi-GI1 trial comparing ivonescimab plus chemotherapy with durvalumab plus chemotherapy in first-line advanced biliary tract cancer.

A Memorial Sloan Kettering Phase II study in previously treated, second-line and later endometrial cancer met its primary endpoint for objective response rate, the proportion of patients whose tumors shrink. Safety was described as manageable, with no new safety signals; results supported study expansion. Summit and ECOG-ACRIN also initiated the U.S. Phase II/III EA2251 biliary tract cancer study. Site activation is expected in the fourth quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
Rhea-AI Summary

Summit Therapeutics (SMMT) entered a collaboration with ECOG-ACRIN to evaluate ivonescimab in a Phase II/III trial for advanced biliary tract cancer. The registration-enabling study, EA2251, will compare first-line ivonescimab plus gemcitabine and cisplatin against pembrolizumab or durvalumab with the same chemotherapy. The randomized, open-label U.S. study will assess safety and efficacy, with overall survival as its primary endpoint. Summit expects clinical trial site activations to begin in Q4 2026.

In August 2026, Akeso reported statistically significant overall survival superiority for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy at a pre-specified interim analysis of HARMONi-GI1. That separate Phase III biliary tract cancer study was conducted in China, with data exclusively generated, managed and analyzed by Akeso.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Rhea-AI Summary

Summit Therapeutics (NASDAQ: SMMT) has initiated a global Phase II study of ivonescimab-based regimens in previously untreated advanced kidney cancer. Clinical trial sites have opened for SMT112-216, conducted with partner Akeso in the U.S. and China. The randomized, open-label study, in which treatment assignments are known, plans to enroll approximately 100 patients with incurable locally advanced or metastatic clear cell renal cell carcinoma who have received no prior systemic therapy for advanced disease.

The study will evaluate safety and efficacy across four treatment groups: ivonescimab plus cadonilimab, ivonescimab plus ipilimumab, ivonescimab alone, and the established standard-of-care combination of nivolumab plus ipilimumab. Cadonilimab is an investigational antibody developed by Akeso. The trial adds to Summit’s separate collaboration with Arcus Biosciences evaluating ivonescimab plus casdatifan in a similar kidney cancer setting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.43%
Tags
-
Rhea-AI Summary

Summit Therapeutics (SMMT) closed AstraZeneca’s (AZN) $2.0 billion equity investment to support development of its investigational cancer therapy ivonescimab.

AstraZeneca purchased approximately 108,955 preferred shares, convertible into Summit common shares at a 1:1,000 ratio. The implied common share price of $18.36 represents a premium to the closing trading price on the investment’s announcement day. Summit plans to use the funds to accelerate development across solid tumors, including combinations with sonesitatug vedotin and Datroway, drugs that deliver chemotherapy through antibodies. The FDA accepted Summit’s ivonescimab marketing application for filing in January 2026, with a target decision date of November 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
Rhea-AI Summary

Daiichi Sankyo (4568) and AstraZeneca (AZN) entered a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate Datroway combined with ivonescimab.

The collaboration covers multiple tumor types, including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer, testing the combination as an initial treatment. Datroway is an antibody-drug conjugate, which links an antibody to a cancer-killing drug, jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Each company will supply its respective compound and contribute to trial costs. AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will retain development and commercial rights to its respective medicine. The agreement establishes planned combination studies; it does not report results from them.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
partnership clinical trial
Rhea-AI Summary

Summit Therapeutics (SMMT) announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab combinations. The agreement covers ivonescimab with Datroway (datopotamab deruxtecan), an antibody linked to a cancer drug that targets TROP2. The companies intend to evaluate the combination across multiple solid tumor settings, including breast and lung cancer, starting with a Phase III trial in first-line triple-negative breast cancer.

AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will supply its respective therapy and contribute to trial costs, while retaining development and commercial rights to its own medicine. Ivonescimab remains investigational and is not approved in Summit’s licensed territories, including the United States and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
partnership clinical trial

FAQ

What is the current stock price of Summit Therapeutics (SMMT)?

Summit Therapeutics (SMMT) last closed at $14.15.

What is the market cap of Summit Therapeutics (SMMT)?

The market cap of Summit Therapeutics (SMMT) is approximately $11.3B.